Skip to main content
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • Standards of Medical Care
    • Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
  • Browse
    • By Topic
    • Issue Archive
    • Scientific Sessions Abstracts
  • Info
    • About the Journal
    • Meet the Editors
    • Reprints & Permissions
    • Journal Policies
    • For Authors
    • For Reviewers
    • For Advertisers
  • Subscriptions
    • Manage Online Access
    • Individual Subscriptions
    • Institutional Subscriptions
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Diabetes Discovery
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • Journal Policies
    • Instructions for Authors
    • Peer Review
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • Standards of Medical Care
    • Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in

Search

  • Advanced search
Diabetes
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
  • Browse
    • By Topic
    • Issue Archive
    • Scientific Sessions Abstracts
  • Info
    • About the Journal
    • Meet the Editors
    • Reprints & Permissions
    • Journal Policies
    • For Authors
    • For Reviewers
    • For Advertisers
  • Subscriptions
    • Manage Online Access
    • Individual Subscriptions
    • Institutional Subscriptions
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Diabetes Discovery
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • Journal Policies
    • Instructions for Authors
    • Peer Review
Commentaries

Beyond Erythropoiesis: Emerging Metabolic Roles of Erythropoietin

  1. Minna Woo1 and
  2. Meredith Hawkins2⇑
  1. 1Toronto General Research Institute and Division of Endocrinology, Department of Medicine, University Health Network, University of Toronto, Toronto, Ontario, Canada
  2. 2Diabetes Research and Training Center, Albert Einstein College of Medicine, Bronx, NY
  1. Corresponding author: Meredith Hawkins, meredith.hawkins{at}einstein.yu.edu.
Diabetes 2014 Jul; 63(7): 2229-2231. https://doi.org/10.2337/db14-0566
Previous
  • Article
  • Figures & Tables
  • Info & Metrics
  • PDF
Loading

Infiltration of inflammatory cells into adipose tissue causes insulin resistance in animal models and is associated with insulin resistance in humans (1,2). Among potential therapeutic approaches, the hormone erythropoietin (EPO) exerts anti-inflammatory effects in a variety of nonerythroid tissues (3), in which the receptor for EPO (EPO-R) is widely expressed (4). Various observations suggest a relationship between EPO and diabetes. There is an increased prevalence of anemia with inadequate EPO response in diabetes (5), and treatment of anemia slows the progression of microvascular and macrovascular complications (6). EPO reduced glucose levels in nondiabetic humans (7) and reduced diet-induced obesity and suppressed gluconeogenesis in rodents (8,9). While EPO increases adipose tissue oxidative metabolism and deletion of EPO in adipocytes results in obesity (10), failure to reproduce this highlights potential genetic and environmental influences (11). EPO has cytoprotective, proliferative, and anti-inflammatory effects in a variety of tissues including pancreatic β-cells, protecting against experimental models of both type 1 and type 2 diabetes (12,13).

In this issue, Alnaeeli et al. (14) elegantly demonstrate a pharmacologic role of EPO in attenuating adipose tissue inflammation prior to changes in body weight. The authors show that EPO-R is disproportionately highly expressed in adipocytes and adipose inflammatory cells, and both pharmacologic and endogenous EPO promote the skewing of adipose macrophages to an alternatively activated, predominantly M2 state. Beneficial roles of EPO are not only abolished when EPO is given to mice lacking EPO-R except in erythroid cells, but these EPO-R−deficient mice have an unopposed proinflammatory phenotype with predominance of M1-activated macrophages. Thus, the predominance of anti-inflammatory M2 macrophages in the lean nondiabetic state may be at least in part restrained by endogenous EPO. As M2 macrophages play an important role in tissue growth and differentiation, beneficial effects of EPO in tissue injury may be achieved through effects on macrophages in addition to a direct cytoprotective role.

While Alnaeeli et al. attributed EPO’s metabolic benefit to effects on adipose tissue macrophages, their finding that EPO expression is high in stromal vascular fraction cells suggests that EPO might exert its effects via other inflammatory cells, which in turn could impact the inflammatory status of adipose macrophages (15). As EPO’s effects on glucose tolerance and inflammation were more striking than on insulin sensitivity, these effects may represent an association rather than a causal relationship. Indeed, some of the observed metabolic effects may be attributable to EPO’s effects on β-cells (12). Could there be an additional role for the brain in mediating EPO’s effects? EPO-R is abundantly expressed in hypothalamic proopiomelanocortin (POMC) neurons (16), and glucose sensing by POMC neurons contributes to regulation of systemic glucose metabolism (17). Another intriguing question is whether some of the insulin-sensitizing effects might be mediated by EPO-induced decreases in systemic iron stores (18), given the known association between iron overload and insulin resistance (19) (Fig. 1).

Figure 1
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1

Erythroid and nonerythroid effects of EPO. Under hypoxic conditions, EPO promotes increased production of red blood cells (RBC). In the hypothalamus, EPO-Rs expressed in POMC-producing neurons regulate food intake and energy expenditure. In white adipose tissue, EPO decreases inflammation, normalizing insulin sensitivity and reducing glucose intolerance. In the pancreas, EPO exerts anti-apoptotic, anti-inflammatory, proliferative, and angiogenic effects on β-cells.

The study by Alnaeeli et al. (14) provides novel insights into both pharmacologic and endogenous roles of EPO that improve glucose tolerance and reduce inflammation. Thus, EPO’s extra-erythropoietic actions may offer novel approaches to diabetes prevention and treatment. As increased risk of thrombogenesis and hypertension (4) suggest that EPO be used cautiously in diabetes, selectively harnessing EPO’s favorable metabolic effects may have therapeutic potential (20).

Article Information

Acknowledgments. The authors wish to acknowledge the intellectual contributions of Drs. Cynthia Luk and Elizabeth Sanchez.

Funding. This work was supported by funding to M.W. from the Canadian Institutes of Health Research (MOP- 81148) and to M.H. from the National Institutes of Health (DK69861 and DK79974) and the American Diabetes Association. M.W. holds a Canada Research Chair in Signal Transduction in Diabetes Pathogenesis. M.H. is a Beeson Scholar of the American Federation for Aging Research.

Duality of Interest. No potential conflicts of interest relevant to this article were reported.

Footnotes

  • See accompanying article, p. 2415.

  • © 2014 by the American Diabetes Association.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.

References

  1. 1.↵
    1. Ferrante AW Jr.
    . The immune cells in adipose tissue. Diabetes Obes Metab 2013;15(Suppl. 3):34–38pmid:24003919
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Koppaka S,
    2. Kehlenbrink S,
    3. Carey M,
    4. et al
    . Reduced adipose tissue macrophage content is associated with improved insulin sensitivity in thiazolidinedione-treated diabetic humans. Diabetes 2013;62:1843–1854pmid:23349486
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    1. Cravedi P,
    2. Manrique J,
    3. Hanlon KE,
    4. et al
    . Immunosuppressive effects of erythropoietin on human alloreactive t cells. J Am Soc Nephrol. 27 March 2014 [Epub ahead of print]
  4. 4.↵
    Fisher JW. Erythropoietin: physiology and pharmacology update. Exp Biol Med (Maywood) 2003;228:1–14
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. Thomas MC,
    2. Cooper ME,
    3. Tsalamandris C,
    4. MacIsaac R,
    5. Jerums G
    . Anemia with impaired erythropoietin response in diabetic patients. Arch Intern Med 2005;165:466–469pmid:15738380
    OpenUrlCrossRefPubMedWeb of Science
  6. 6.↵
    1. McGill JB,
    2. Bell DS
    . Anemia and the role of erythropoietin in diabetes. J Diabetes Complications 2006;20:262–272pmid:16798479
    OpenUrlCrossRefPubMedWeb of Science
  7. 7.↵
    1. Drüeke TB,
    2. Locatelli F,
    3. Clyne N,
    4. et al.,
    5. CREATE Investigators
    . Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006;355:2071–2084pmid:17108342
    OpenUrlCrossRefPubMedWeb of Science
  8. 8.↵
    1. Katz O,
    2. Stuible M,
    3. Golishevski N,
    4. et al
    . Erythropoietin treatment leads to reduced blood glucose levels and body mass: insights from murine models. J Endocrinol 2010;205:87–95pmid:20061512
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. Meng R,
    2. Zhu D,
    3. Bi Y,
    4. Yang D,
    5. Wang Y
    . Erythropoietin inhibits gluconeogenesis and inflammation in the liver and improves glucose intolerance in high-fat diet-fed mice. PLoS One 2013;8:e53557pmid:23326455
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Wang L,
    2. Teng R,
    3. Di L,
    4. et al
    . PPARα and Sirt1 mediate erythropoietin action in increasing metabolic activity and browning of white adipocytes to protect against obesity and metabolic disorders. Diabetes 2013;62:4122–4131pmid:23990359
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    1. Luk CT,
    2. Shi SY,
    3. Choi D,
    4. Cai EP,
    5. Schroer SA,
    6. Woo M
    . In vivo knockdown of adipocyte erythropoietin receptor does not alter glucose or energy homeostasis. Endocrinology 2013;154:3652–3659pmid:23885016
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Choi D,
    2. Schroer SA,
    3. Lu SY,
    4. et al
    . Erythropoietin protects against diabetes through direct effects on pancreatic beta cells. J Exp Med 2010;207:2831–2842pmid:21149549
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    1. Choi D,
    2. Retnakaran R,
    3. Woo M
    . The extra-hematopoietic role of erythropoietin in diabetes mellitus. Curr Diabetes Rev 2011;7:284–290pmid:21644916
    OpenUrlCrossRefPubMed
  14. 14.↵
    1. Alnaeeli M,
    2. Raaka BM,
    3. Gavrilova O,
    4. Teng R,
    5. Chanturiya T,
    6. Noguchi CT
    . Erythropoietin signaling: a novel regulator of white adipose tissue inflammation during diet-induced obesity. Diabetes 2014;63:2415–2431pmid:24647735
    OpenUrlAbstract/FREE Full Text
  15. 15.↵
    1. Har D,
    2. Carey M,
    3. Hawkins M
    . Coordinated regulation of adipose tissue macrophages by cellular and nutritional signals. J Investig Med 2013;61:937–941pmid:23863720
    OpenUrlPubMed
  16. 16.↵
    1. Teng R,
    2. Gavrilova O,
    3. Suzuki N,
    4. et al
    . Disrupted erythropoietin signalling promotes obesity and alters hypothalamus proopiomelanocortin production. Nat Commun 2011;2:520pmid:22044999
    OpenUrlCrossRefPubMed
  17. 17.↵
    1. Carey M,
    2. Kehlenbrink S,
    3. Hawkins M
    . Evidence for central regulation of glucose metabolism. J Biol Chem 2013;288:34981–34988pmid:24142701
    OpenUrlAbstract/FREE Full Text
  18. 18.↵
    Goodnough LT, Skikne B, and Brugnara C. Erythropoietin, iron, and erythropoiesis. Blood 2000;96:823−833
  19. 19.↵
    1. Fernández-Real JM,
    2. Ricart-Engel W,
    3. Arroyo E,
    4. et al
    . Serum ferritin as a component of the insulin resistance syndrome. Diabetes Care 1998;21:62–68pmid:9580307
    OpenUrlAbstract/FREE Full Text
  20. 20.↵
    1. Brines M,
    2. Patel NS,
    3. Villa P,
    4. et al
    . Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin. Proc Natl Acad Sci U S A 2008;105:10925–10930pmid:18676614
    OpenUrlAbstract/FREE Full Text
View Abstract
Previous
Back to top
Diabetes: 63 (7)

In this Issue

July 2014, 63(7)
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by Author
  • Masthead (PDF)
Sign up to receive current issue alerts
View Selected Citations (0)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Beyond Erythropoiesis: Emerging Metabolic Roles of Erythropoietin
(Your Name) has forwarded a page to you from Diabetes
(Your Name) thought you would like to see this page from the Diabetes web site.
Citation Tools
Beyond Erythropoiesis: Emerging Metabolic Roles of Erythropoietin
Minna Woo, Meredith Hawkins
Diabetes Jul 2014, 63 (7) 2229-2231; DOI: 10.2337/db14-0566

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

Beyond Erythropoiesis: Emerging Metabolic Roles of Erythropoietin
Minna Woo, Meredith Hawkins
Diabetes Jul 2014, 63 (7) 2229-2231; DOI: 10.2337/db14-0566
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Article Information
    • Footnotes
    • References
  • Figures & Tables
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • A Weighty Matter: Can PUFAs in Pregnancy Prevent Obesity?
  • SRGAP2a: A New Player That Modulates Podocyte Cytoskeleton and Injury in Diabetes
  • Values and Limitations of Targeting lncRNAs in Diabetic Nephropathy
Show more Commentaries

Similar Articles

Navigate

  • Current Issue
  • Online Ahead of Print
  • Scientific Sessions Abstracts
  • Collections
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • For Advertisers
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes Care
  • Clinical Diabetes
  • Diabetes Spectrum
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Scientific Sessions Abstracts
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2018 by the American Diabetes Association. Diabetes Print ISSN: 0012-1797, Online ISSN: 1939-327X.